NCT05548387View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 2, 2022

Primary Completion Date

November 10, 2022

Study Completion Date

November 10, 2022

Conditions
Healthy
Interventions
DRUG

HCP2202

Take it once per period.

DRUG

RLD2202

Take it once per period.

DRUG

RLD2203

Take it once per period.

Trial Locations (1)

Unknown

Chonbuk National University Hospital, Jeonju

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT05548387 - A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers | Biotech Hunter | Biotech Hunter